Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable ...
Notably, 370 (83%) participants had squamous cell carcinoma, 215 (48%) had received previous chemoradiotherapy, 116 (26%) had a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of ...
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
In a significant development for cancer treatment, Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved its innovative device, Optune Lua®, for use in ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback